SEC Form 4 · accession 0001203311-18-000099

SEATTLE GENETICS INC /WA · SGEN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Technical Officer

Period of report

Nov 30, 2018

Accepted (ET)

Dec 4, 2018 · 7:37 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001060736

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F2,F3	Nov 30, 2018	S	4,600	$62.09	D	172,729	D
Common Stock^F4,F3	Nov 30, 2018	S	400	$62.76	D	172,329	D
Common Stock^F3	Nov 30, 2018	M	5,000	$12.00	A	177,329	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F5	$12.00	Nov 30, 2018	M	5,000	D	—	Aug 27, 2020	Common Stock	5,000	36,498	D

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2Reflects sales of common stock executed in multiple transactions at prices ranging from $61.62 to $62.60. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
F4Reflects sales of common stock executed in multiple transactions at prices ranging from $62.64 to $62.87. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5Shares vested at a rate of 25% on 8/27/11 and monthly thereafter until all the shares were fully vested on 8/27/14.